Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study
Status: Recruiting
Location: See all (6) locations...
Study Type: Observational
SUMMARY
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Has a confirmed diagnosis of moderate-to-severe plaque psoriasis
• Participant must sign an informed consent form allowing source data verification in accordance with local requirements
• Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments
• No previous exposure to biological treatment, including guselkumab (bio-naive patient)
• Intended for the treatment with guselkumab according to the approved indication
Locations
Other Locations
Romania
Mihaila G. Georgiana - Cabinet Medical Individual Dermatovenerologie
RECRUITING
Bârlad
Qualimed SRL
RECRUITING
Brasov
Spitalul Clinic Colentina
RECRUITING
Bucharest
Spitalul Clinic Colentina 1
RECRUITING
Bucharest
Derma Lux SRL
RECRUITING
Iași
Dr Tirziu Dermato Chirurgie SRL
RECRUITING
Timișoara
Contact Information
Primary
Study Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Time Frame
Start Date: 2026-05-15
Estimated Completion Date: 2028-11-10
Participants
Target number of participants: 200
Treatments
Group 1: Participants with Moderate-to-Severe Plaque Psoriasis
Participants with confirmed diagnosis of moderate-to-severe plaque psoriasis who have never been treated with biological treatment before, and receiving guselkumab as per routine clinical practice will be enrolled. Only data available per clinical practice will be collected within this study. The primary data source for this study will be the medical records of each participant.
Related Therapeutic Areas
Sponsors
Leads: Janssen Research & Development, LLC